Providence Health Care has established a reputation as one of the leading centres for cardiology research and treatment in Canada. Medtronic of Canada is a major supplier of therapeutic cardiac equipment, technology and implantable devices, and works closely with Providence Healthcare to advance the science of cardiac treatment.
Providence Healthcare has established a reputation as one of the leading centres for cardiovascular research and treatment in Canada. Pfizer Global Pharmaceuticals Canada is a major provider of pharmaceuticals used in cardiovascular treatment, and has an active research agenda aimed at improving the effectiveness of non]invasive diagnosis and treatment in this field. Pfizer and Providence Healthcare are collaborating on this research in order to develop more effective pharmacological treatments for atherosclerosis.
It is well known in Cardiology that chronic right ventricular apex (RVA) pacing (using a pacemaker to regulate heart rhythm by pacing the lower chamber of the heart near the base) might be detrimental to heart function. Right Ventricular Apex (RVA) pacing is the most commonly used for patients. Alternate sites such as right ventricular (RV) pacing, including right ventricular septum and right ventricular outflow tract (RVOT), have not been shown to be definitely superior over RVA pacing.
Implantable cardioverter defibrillators (ICD), life‐saving devices that may prevent sudden cardiac death from cardiac arrhythmias, are implanted in people who have had cardiac arrests and increasingly in people with severe heart failure who are at risk for a primary ventricular arrhythmia. The clinical benefits of ICD implantation contrasts with evidence suggesting ICDs may also have untoward effects on recipients’ quality of life and psycho‐emotional status. Yet, the research on ICDs and patient‐reported outcomes is very limited and has produced inconclusive findings.